SCHEMBL1250573

SCHEMBL1250573

O=C1NC(=O)/C(=C/c2ccc(Br)cc2)S1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 8/20 1.00
PIM2 Q9P1W9 8/20 1.00
MAOA P21397 4/20 1.00
MAOB P27338 3/20 1.00
CISD1 Q9NZ45 7/20 0.75
MEN1 O00255 1/20 0.75
KMT2A Q03164 1/20 0.75
TDP1 Q9NUW8 2/20 0.72
PIM3 Q86V86 1/20 0.70
HPGD P15428 2/20 0.68
GSK3B P49841 2/20 0.68
AKR1B1 P15121 2/20 0.68
RAB9A P51151 1/20 0.68
TTR P02766 1/20 0.62
INSR P06213 1/20 0.62
IGF1R P08069 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2544417 1.00 PIM1 (1.00) PIM1PIM2MAOAMAOBCISD1
SCHEMBL1250576 1.00 PIM1 (1.00) PIM1PIM2MAOAMAOBCISD1
SCHEMBL1249975 0.83 PIM1 (1.00) PIM1PIM2MAOAMAOBCISD1
SCHEMBL2548313 0.83 PIM1 (1.00) PIM1PIM2MAOAMAOBCISD1
SCHEMBL1249973 0.83 PIM1 (1.00) PIM1PIM2MAOAMAOBCISD1
SCHEMBL1250085 0.83 MAOB (0.68) PIM1PIM2MAOAMAOBCISD1
SCHEMBL1250086 0.83 MAOB (0.68) PIM1PIM2MAOAMAOBCISD1
SCHEMBL1250387 0.82 PIM1 (1.00) PIM1PIM2MAOAMAOBCISD1
SCHEMBL4862901 0.82 PIM1 (0.72) PIM1PIM2MAOAMAOBCISD1
SCHEMBL211085 0.82 PIM1 (1.00) PIM1PIM2MAOAMAOBCISD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 US claimed
EP-2217235-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER Musc Foundation for Research Development (US) 2010-08-18 EP claimed
WO-2009064486-A9 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUND FOR RES DEV (US) 2009-07-16 WO claimed
WO-2009064486-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2009-05-22 WO claimed
WO-2019154958-A1 USE OF MODULATORS OF NEET PROTEINS FOR THE TREATMENT OF INFECTION ENYO PHARMA (FR) 2019-08-15 WO disclosed
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 US disclosed
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 US disclosed
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 US disclosed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
EP-2217235-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER Musc Foundation for Research Development (US) 2010-08-18 EP disclosed
WO-2004080481-A1 NOVEL NPH INSULIN PREPARATIONS NOVO NORDISK A/S (DK) 2004-09-23 WO disclosed
WO-2004080480-A1 PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN NOVO NORDISK A/S (DK) 2004-09-23 WO disclosed
WO-2004056347-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed
EP-1429763-A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK A/S (DK) 2004-06-23 EP disclosed
US-20040115626-A1 Human pgc-1 promoter ASTELLAS PHARMA INC. (JP) 2004-06-17 US disclosed
US-20030229120-A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer NOVO NORDISK A/S (DK) 2003-12-11 US disclosed
WO-2003027081-A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK A/S (DK) 2003-04-03 WO disclosed
EP-1284291-A1 HUMAN PGC-1 PROMOTER YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885MAOA 4313/4885
US-20030229120-A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer IAPP, IRS1, GPR119 PIM1 4412/4885PIM2 4504/4885MAOA 4704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.